– Oral Presentation and Poster Show Ability of Lead Candidate, Eravacycline, to Help Protect Against Community-Acquired, Complicated Intra-Abdominal Infections –
– Poster Shows Usefulness of Preclinical Candidate, TP-271, Against Community-Acquired Bacterial Pneumonia
WATERTOWN, MA, USA I April 29, 2013 I Tetraphase Pharmaceuticals, Inc. (TTPH) today announced that it has presented results from studies that demonstrate efficacy of two next-generation antibiotic candidates against community-acquired multi-drug resistant (MDR) infections. These studies – which support the efficacy of the company’s lead candidate, eravacycline, in the treatment of patients with community-acquired, complicated intra-abdominal infections (cIAIs), as well as the potential of pre-clinical candidate TP-271’s activity against community-acquired bacterial pneumonia (CABP) – were described in one oral presentation and two poster presentations at the 23rd European Congress of Clinical Microbiology and Infectious Disease (ECCMID). The Congress occurs from April 27 to 30, 2013 in Berlin, Germany.
“These data continue to demonstrate the potential of our antibiotic franchise, both in terms of our lead candidate eravacycline, and the strength of our pre-clinical program, ” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “Antibiotic resistance, particularly among the difficult-to-treat populations with Gram-negative infections, represents a potential global health crisis. We are pleased by the results that our compounds display, particularly in the crucial areas of multi-drug resistant, community-acquired infections.”
The oral presentation, which focused on results from a global Phase 2 trial, examined eravacycline compared to standard-of-care ertapenem for the treatment of community-acquired cIAIs. Results showed that eravacycline demonstrated efficacy in all populations at all study time points when examining both the microbiological activity of the pathogens and the clinical cure rates. The findings strongly support the use of eravacycline in the treatment of cIAI, including those hard-to-treat patients with multi-drug resistant gram-negative infections.
Following are details for each of Tetraphase’s three presentations:
- “Characterization of baseline pathogens and microbiological eradiation in a phase 2 trial for treatment of complicated intra-abdominal infections comparing eravacycline (TP-434) to ertapenem.” C. Fyfe, J. Deane, T. Grossman, P. Horn, G. Moore, D. Sahm, J. Studeny, S. Walpole, and J. Sutcliffe. Presented as an oral presentation (#277) on Sunday, 28 April 2013 at 12:06 p.m. CEST as part of ECCMID’s session on “Clinical trials of antimicrobial agents”
- “The fluorocycline TP-271 is potent against major complicated community-acquired bacterial pneumonia (CABP) pathogens.” T. H. Grossman, C. Fyfe, W. O’Brien, D. E. Low, M. B. Minyard, K. Waites, J. Dubois, J. A. Sutcliffe. Presented as a poster (# 1641) on Sunday April 28, 2013 from 1:30 – 2:30 p.m. CEST as part of the session “New antibacterial agents other than beta-lactams.”
- “Time to defervescence as an early marker of clinical response in patients with complicated intra-abdominal infections treated with eravacycline or ertapenem.” P. Horn, J. Sutcliffe, S. Walpole. Presented as a poster (# 2107) on Monday, April 29 from 1:30 – 2:30 p.m. CEST as part of the session “Endocarditis and other serious infections– clinical observations.”
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.
SOURCE: Tetraphase
Post Views: 208
– Oral Presentation and Poster Show Ability of Lead Candidate, Eravacycline, to Help Protect Against Community-Acquired, Complicated Intra-Abdominal Infections –
– Poster Shows Usefulness of Preclinical Candidate, TP-271, Against Community-Acquired Bacterial Pneumonia
WATERTOWN, MA, USA I April 29, 2013 I Tetraphase Pharmaceuticals, Inc. (TTPH) today announced that it has presented results from studies that demonstrate efficacy of two next-generation antibiotic candidates against community-acquired multi-drug resistant (MDR) infections. These studies – which support the efficacy of the company’s lead candidate, eravacycline, in the treatment of patients with community-acquired, complicated intra-abdominal infections (cIAIs), as well as the potential of pre-clinical candidate TP-271’s activity against community-acquired bacterial pneumonia (CABP) – were described in one oral presentation and two poster presentations at the 23rd European Congress of Clinical Microbiology and Infectious Disease (ECCMID). The Congress occurs from April 27 to 30, 2013 in Berlin, Germany.
“These data continue to demonstrate the potential of our antibiotic franchise, both in terms of our lead candidate eravacycline, and the strength of our pre-clinical program, ” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “Antibiotic resistance, particularly among the difficult-to-treat populations with Gram-negative infections, represents a potential global health crisis. We are pleased by the results that our compounds display, particularly in the crucial areas of multi-drug resistant, community-acquired infections.”
The oral presentation, which focused on results from a global Phase 2 trial, examined eravacycline compared to standard-of-care ertapenem for the treatment of community-acquired cIAIs. Results showed that eravacycline demonstrated efficacy in all populations at all study time points when examining both the microbiological activity of the pathogens and the clinical cure rates. The findings strongly support the use of eravacycline in the treatment of cIAI, including those hard-to-treat patients with multi-drug resistant gram-negative infections.
Following are details for each of Tetraphase’s three presentations:
- “Characterization of baseline pathogens and microbiological eradiation in a phase 2 trial for treatment of complicated intra-abdominal infections comparing eravacycline (TP-434) to ertapenem.” C. Fyfe, J. Deane, T. Grossman, P. Horn, G. Moore, D. Sahm, J. Studeny, S. Walpole, and J. Sutcliffe. Presented as an oral presentation (#277) on Sunday, 28 April 2013 at 12:06 p.m. CEST as part of ECCMID’s session on “Clinical trials of antimicrobial agents”
- “The fluorocycline TP-271 is potent against major complicated community-acquired bacterial pneumonia (CABP) pathogens.” T. H. Grossman, C. Fyfe, W. O’Brien, D. E. Low, M. B. Minyard, K. Waites, J. Dubois, J. A. Sutcliffe. Presented as a poster (# 1641) on Sunday April 28, 2013 from 1:30 – 2:30 p.m. CEST as part of the session “New antibacterial agents other than beta-lactams.”
- “Time to defervescence as an early marker of clinical response in patients with complicated intra-abdominal infections treated with eravacycline or ertapenem.” P. Horn, J. Sutcliffe, S. Walpole. Presented as a poster (# 2107) on Monday, April 29 from 1:30 – 2:30 p.m. CEST as part of the session “Endocarditis and other serious infections– clinical observations.”
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase’s lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections.
SOURCE: Tetraphase
Post Views: 208
